Welcome to Avipep Therapeutics

Avipep Therapeutics is developing proprietary Avibody™-drug conjugates for patients fighting relapsed and refractory cancer. Avibodies represent an improved platform for the next generation of ADCs.

Avibodies™ are small, stable, high avidity antibody-derivatives that have superior biodistribution and tumor penetration compared with traditional intact IgGs. Clinical trial results in cancer patients have shown that Avibodies can rapidly and efficiently penetrate tumors. They durably persist within the tumor for weeks while rapidly clearing from the systemic circulation within hours.

Avibodies can deliver highly potent payloads with far less toxicity and can be reformatted from existing intact antibodies. Please contact us to discuss collaboration or license.

Download poster from World ADC, Oct 2019